Research Progress of Cutaneous Squamous and Basal Cell Carcinomas (Volume II)

Dear Colleagues,

This Special Issue is the second edition of the Special Issue “Research Progress of Cutaneous Squamous and Basal Cell Carcinomas”, available at https://www.mdpi.com/journal/cancers/special_issues/CSCC_cancers.

We are pleased to invite you to contribute to this Special Issue, which aims to explore the relationship between the TIME (tumor immune microenvironment) and the development, progression, and treatment of cSCC.

More than a million new cases of cutaneous squamous cell carcinoma (cSCC) are diagnosed yearly in the USA, and their incidence is expected to increase worldwide as the population ages. As opposed to other nonmelanoma skin cancers, cSCC is associated with an increased rate of distant metastasis and elevated morbimortality.

Immunosuppression is directly related to the risk of cSCC development, and chronically immunosuppressed individuals, such as organ transplant recipients and those with hematological malignancies, represent a significant portion of cSCC patients. Unfortunately, since immunodeficiency is a major risk factor for metastatic dissemination, these vulnerable patients are more prone to developing advanced disease.

Chronic ultraviolet exposure (UV) is a major etiological factor for cSCC and promotes a unique mutation signature in these tumors. It is also an important immunosuppressive agent and may contribute to a reduction in local immunosurveillance, favoring pro-tumorigenic changes such as skin infection by beta human papillomavirus (HPV), which is considered an important promoter of skin carcinogenesis.

Although the relevance of the tumor immune microenvironment (TIME) in the initiation and progression of cSCC is widely accepted, our understanding of the intricate relationship between the TIME and the cSCC is limited. Consequently, the development and application of new measures for the prevention and treatment of cSCC, especially those linked to immunomodulation, require further exploration.

Original research articles and reviews are welcome. We look forward to receiving your contributions.

Dr. Moran Amit
Dr. Frederico O. Gleber-Netto
Dr. Neil D. Gross
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-anonymized peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.